However, STING deficiency is common in several cancer entities due to the anti-tumorigenic and immune-activating role of STING signaling [286,287,288] and data suggest that, consequently, oncolytic viruses benefit from STING loss due to a decreased antiviral IFN response [287,288]. This evidence concerns the gene STING1 and cancer.